April 5 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie’s blockbuster arthritis treatment ...
Seattle-based Sana Biotechnology Inc. (Nasdaq: SANA) is losing its research and development lead. In a Thursday filing with ...
Amgen has been busy with a couple of multi-billion dollar acquisitions over the past few years. While they should create growth opportunities, the drugmaker has also taken on quite a bit of debt.
The Westchester-based unit of New Jersey-based Kenvue is closing its corporate headquarters at 6080 West Center Drive to ...
As with Epogen, the initial discoveries that laid the basis for the drug had ... That decade of investment and research was paying off. In 1992, Amgen hit the billion dollars sales mark and ...
Amgen, with its obesity candidate MariTide and other promising treatments in its pipeline, could potentially surpass Eli Lilly in the obesity market. Amgen's stock is undervalued compared to Eli ...
April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due ... with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira ...
(Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales ... its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita ...